| Molecular mechanisms of diabetes and atherosclerosis: Role of adiponectin. | |
| | |
MedLine Citation:
|
PMID: 22236026 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Type 2 diabetes mellitus (T2DM) is a disease characterized by inadequate beta-cell response due to progressive insulin resistance that typically accompanies physical inactivity and weight gain. T2DM is associated with substantial morbidity and mortality related to the associated atherosclerotic cardiovascular risks and diabetic vasculopathies, including microangiopathies (e.g., blindness and renal failure) and macroangiopathies (atherosclerosis). The increasing global prevalence of T2DM is linked to the rising rates of obesity, especially abdominal obesity. Visceral fat accumulation is upstream of obesity-related disorders including atherosclerotic cardiovascular disease (ACVD), and is associated with impaired insulin sensitivity and atherosclerosis through dysregulated production of adipocytokines, especially hypoadiponectinemia. This review article discusses the pathophysiological mechanisms responsible for T2DM and atherosclerosis, focusing on adiponectin. Clinical and experimental studies have shown that hypoadiponectinemia contributes to a variety of life style-related diseases including T2DM and atherosclerosis. It is likely that life-style modification, visceral fat reduction and use of medications that increase serum adiponectin levels (e.g., rimonabant, thiazolidinediones, fibrates, angiotensin receptor blocker and mineralocorticoid receptor blockade) when provided in combination can improve hypoadiponectinemia and thus prevent the development of life style-related diseases including T2DM and ACVD. |
| | |
Authors:
|
Ken Kishida; Tohru Funahashi; Iichiro Shimomura |
Related Documents
:
|
21243856 - Eligibility of nigerians with type 2 diabetes mellitus for inhaled insulin. 6811566 - Antidiabetic effects of lithium. 22077236 - Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. 18268786 - Evolutionary responses by native species to major anthropogenic changes to their ecosys... 10511896 - Plasma lipoprotein (a) levels in turkish niddm patients with and without vascular diabe... 14694226 - Relationship of adiposity to subclinical atherosclerosis in obese patients with type 2 ... |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2012-1-11 |
Journal Detail:
|
Title: Endocrine, metabolic & immune disorders drug targets Volume: - ISSN: 2212-3873 ISO Abbreviation: Endocr Metab Immune Disord Drug Targets Publication Date: 2012 Jan |
Date Detail:
|
Created Date: 2012-1-12 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101269157 Medline TA: Endocr Metab Immune Disord Drug Targets Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Department of Metabolism and Atherosclerosis, Graduate School of Medicine, Osaka University 2-2 B-5, Yamada-oka, Suita, Osaka 565-0871, Japan. kkishida@imed2.med.osaka-u.ac.jp. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Cardiac effects of HDL and its components on diabetic cardiomyopathy.
Next Document: Diabetes-induced epigenetic signature in vascular cells.